Library

X
feed icon rss

Your email was sent successfully. Check your inbox.

An error occurred while sending the email. Please try again.

Proceed reservation?

Export
  • 1
    Electronic Resource
    Electronic Resource
    Antimigraine drugs (1999)
    Springer
    Journal of neurology 246 (1999), S. 515-519 
    Details
    ISSN: 1432-1459
    Keywords: Key words Migraine attack ; 5-HT1B/1D agonists ; Analgesics ; Ergotamine
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Notes: Abstract Migraine is a paroxysmal disorder characterized by attacks of headache, nausea, vomiting, photophobia, phonophobia, and malaise. This review summarizes new treatment options for therapy of the acute attack. Mild or moderate migraine attacks are treated with antiemetics followed by analgesics such as aspirin, paracetamol, nonsteroidal anti-inflammatory drugs, or antiemetics combined with ergotamine or dihydroergotamine. Sumatriptan, a specific serotonin (5-HT)1B/D agonist is used when attacks do not respond to ergotamine, or when intolerable side effects occur. The new migraine drugs zolmitriptan, naratriptan, rizatriptan, and eletriptan differ slightly in their pharmacological profiles, which translates into minor differences in efficacy, headache recurrence, and side effects. New drugs in migraine prophylaxis include cyclandelate, valproic acid and magnesium.
    Type of Medium: Electronic Resource
    URL: http://dx.doi.org/10.1007/s004150050396
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
    Paper (German National Licenses)
    Fulltext
  • 2
    Electronic Resource
    Electronic Resource
    Schlaganfallprävention mit Thrombozytenfunktionshemmern und Antikoagulantien (2000)
    Springer
    Der Internist 41 (2000), S. S040 
    Details
    ISSN: 1432-1289
    Keywords: Schlüsselwörter ; Schlaganfall ; Sekundärprävention ; Thrombozytenfunktionshemmer ; Acetylsalicyclsäure ; Ticlopidin ; Clopidogrel ; Dipyridamol ; Antikoagulation
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Notes: Zum Thema Die Sekundärprävention umfasst Maßnahmen zur Verhinderung eines Schlaganfalls, nachdem zuvor bereits ein flüchtiger, leichter oder vollendeter Insult aufgetreten ist. Wert und Notwendigkeit einer Sekundärprävention des Schlaganfalls nach einer transienten ischämischen Attacke (TIA) oder einem ischämischen Insult sind unbestritten. Das Spektrum der möglichen Therapieprinzipien richtet sich nach der Pathophysiologie des Schlaganfalls und umfasst den Einsatz von Thrombozytenfunktionshemmern (TFH), Antikoagulation und die Karotisendarterektomie. In der Zwischenzeit gibt es mehr als 50 kontrollierte Studien zu diesem Thema, wobei sich der größte Teil der Studien mit TFH, hier vor allem Acetylsalicylsäure (ASS) beschäftigen. Ein Vergleich der bisher vorliegenden Studien wird aber durch unterschiedliche Patientenpopulationen (Studien mit ausschließlich TIA Patienten versus Patienten mit Schlaganfall), Endpunkte (Schlaganfall versus kombiniertem Endpunkt aus Schlaganfall, Myokardinfarkt und Tod) und Behandlungsprotokolle (Monotherapie versus Kombinationstherapie) erschwert. Der vorliegende Beitrag gibt einen Überblick zu den relevanten Studien und den sich daraus ergebenden Empfehlungen zur Sekundärprävention des Schlaganfalls.
    Type of Medium: Electronic Resource
    URL: http://dx.doi.org/10.1007/s001080070006
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
    Paper (German National Licenses)
    Fulltext
  • 3
    Electronic Resource
    Electronic Resource
    Ergotamine, flunarizine and sumatriptan do not change cerebral blood flow velocity in normal subjects and migraneurs (1991)
    Springer
    Journal of neurology 238 (1991), S. 245-250 
    Details
    ISSN: 1432-1459
    Keywords: Migraine ; Cerebral blood flow velocity ; Ergotamine ; Flunarizine ; Sumatriptan
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Notes: Summary Changes in the diameter of extracranial and intracranial arteries resulting in changes in cerebral blood flow have previously been assumed to be the most important pathophysiological factor in migraine. To test this hypothesis 20 normal subjects, and three groups of patients (n=29) with migraine were investigated by means of transcranial Doppler sonography. Blood flow velocities in the middle cerebral (MCA) and in basilar (BA) arteries were measured. Data from patients were obtained in the interval between migraine attacks, during migraine attacks and following treatment with either ergotamine (0.5 mg i.m.; n=10); flunarizine, a calcium overload blocker (20 mg i.v.; n=13); or a 5-HT1-like agonist (sumatriptan, 4 mg s.c.; n=6). Ergotamine and sumatriptan are constrictors of cerebral arteries in animal experiments. The arithemtic mean of flow velocity in the BA was reduced in normal subjects (45 cm/s) as compared with patients with migraine measured in between attacks (53 cm/s). Mean flow velocity in MCA was not different in normals (72.5 cm/s) as compared with migraineurs (75 cm/s). Neither ergotamine nor the 5-HT1 agonist and flunarizine resulted in a significant change in blood flow velocity in MCA and BA. This was true irrespective of whether the drugs were given in the headache-free period, during a migraine attack or during the withdrawal phase of drug-induced headache. Ergotamine was effective in improving headache during migraine attacks and sumatriptan attenuated headache during drug withdrawal from chronic analgesic intake. These results indicate that the action of ergotamine and the 5-HT1-receptor agonist is probably not mediated by their vasoconstrictor action on cerebral arteries.
    Type of Medium: Electronic Resource
    URL: http://dx.doi.org/10.1007/BF00319734
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
    Paper (German National Licenses)
    Fulltext
Close ⊗
This website uses cookies and the analysis tool Matomo. More information can be found here...